Government-Owned Inventions; Availability for Licensing, 53489-53490 [2018-23066]

Download as PDF Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 8A31, Bethesda, MD 20892, Phone: (301) 451–4460, Email: Linda.Porter@nih.gov. Please Note: Any member of the public interested in submitting written comments to the Committee must notify the Contact Person listed on this notice by 5:00 p.m. ET on Friday, November 2, 2018, with their request. Interested individuals and representatives of organizations must submit a written/electronic copy of the oral statement/comments including a brief description of the organization represented by 5:00 p.m. ET on Friday, November 9, 2018. Statements submitted will be shared with the committee members and become a part of the public record. The meeting will be open to the public and accessible by live Webcast. Individuals who participate in person or by using these electronic services and who need special assistance, such as captioning or other reasonable accommodations, should submit a request to the Contact Person listed on this notice at least seven days prior to the meeting. As a part of security procedures, attendees should be prepared to present a photo ID during the security process to get on the NIH campus. For a full description, please see: http://www.nih.gov/about/ visitorsecurity.htm. Information about the IPRCC is available on the website: http://iprcc.nih.gov/. Dated: October 16, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23032 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSK30JT082PROD with NOTICES National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; NIA AD/ ADRD Research Collaboratory. Date: November 20, 2018. VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 Time: 1:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute on Aging, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Isis S. Mikhail, MD, MPH, DRPH, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7704, mikhaili@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) Dated: October 17, 2018. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23068 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Eye Institute Special Emphasis Panel; Secondary Data Analysis (R21) Grant Applications. Date: November 19, 2018. Time: 3:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call). Contact Person: Brian Hoshaw, Ph.D., Scientific Review Officer, National Eye Institute, National Institutes of Health, Division of Extramural Research, 5635 Fishers Lane, Suite 1300, Rockville, MD 20892, 301–451–2020, hoshawb@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 53489 Dated: October 17, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–23034 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Dr. Vince Contreras, 240–669–2823; vince.contreras@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Fusion Glycoprotein Vaccine for Human Metapneumovirus Description of Technology: Human metapneumovirus (hMPV), a negative, single-stranded RNA virus, accounts for approximately 5–15% of infant respiratory tract infections and poses a severe risk of disease and hospitalization in both the elderly and the immunocompromised. Investigators at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have generated an hMPV fusion glycoprotein (‘‘F protein’’) stabilized in a prefusion conformation. Stabilizing this prefusion conformation of the F protein reveals an immunodominant site which makes it an ideal vaccine immunogen. The E:\FR\FM\23OCN1.SGM 23OCN1 53490 Federal Register / Vol. 83, No. 205 / Tuesday, October 23, 2018 / Notices prefusion stabilized F protein immunogen can be delivered as either an isolated homotrimer or trimers displayed on a nanoparticle. These immunogens elicit broad and potent hMPV-neutralizing antibodies. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications: • Vaccine for prevention of human metapneumovirus infection Competitive Advantages: • No human metapneumovirus vaccine is currently available Development Stage: • In vitro data available • In vivo animal data available Inventors: Peter D. Kwong, (NIAID), Michael Gordon Joyce (NIAID), Peter L. Collins (NIAID), Ursula J. Buchholz (NIAID), Guillaume Stewart-Jones (NIAID), Baoshan Zhang (NIAID), Yongping Yang (NIAID), Davide Corti (Institute for Research in Biomedicine), Antonio Lanzavecchia (Institute for Research in Biomedicine). Intellectual Property: HHS Reference Number E–260–2014 includes U.S. Provisional Patent Application No. 62/ 096,744, filed December 24, 2014; PCT Application No. PCT/IB2015/059991, filed December 24, 2015; U.S. Patent Application No 15/539,640 filed June 23, 2017; EPO Patent Application No. 15831073.0, filed 21 July 2017. Licensing Contact: Dr. Vince Contreras, 240–669–2823; vince.contreras@nih.gov. Dated: October 10, 2018. Suzanne M. Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2018–23066 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSK30JT082PROD with NOTICES National Institute on Aging; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute on Aging Special Emphasis Panel, October 17, 2018, 09:00 a.m. to October 17, 2018, 01:00 p.m., Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814 which was published in the Federal Register on September 20, 2018, 83 FR 47634. The meeting notice is amended to change the date of the meeting from VerDate Sep<11>2014 20:20 Oct 22, 2018 Jkt 247001 October 17, 2018 to October 17–18, 2018. The meeting is closed to the public. Dated: October 17, 2018. Melanie J. Pantoja, Program Analyst,Office of Federal Advisory Committee Policy. [FR Doc. 2018–23067 Filed 10–22–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: AIDS and Related Research Integrated Review Group; Population and Public Health Approaches to HIV/AIDS Study Section. Date: November 8–9, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton Suites—Old Town Alexandria, 801 N Saint Asaph St., Alexandria, VA 22314. Contact Person: Jose H. Guerrier, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5222, MSC 7852, Bethesda, MD 20892, 301–435– 1137, guerriej@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; AIDS and Related Research. Date: November 9, 2018. Time: 3:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Barna Dey, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, Bethesda, MD 20892, 301–451–2796, bdey@mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Radiation Therapeutics and Biology. PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 Date: November 14, 2018. Time: 12:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Nicholas J. Donato, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4040, Bethesda, MD 20892, 301–827–4810, nick.donato@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Cardiovascular and Surgical Devices. Date: November 15–16, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Crystal Gateway Marriott, 1700 Jefferson Davis Highway, Arlington, VA 22202. Contact Person: Jan Li, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5106, Bethesda, MD 20892, 301.402.9607, Jan.Li@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Instrumentation, Environmental, and Occupational Safety. Date: November 15–16, 2018. Time: 8:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Contact Person: Marie-Jose Belanger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 6188 MSC 7804, Bethesda, MD 20892, 301–435–1267, belangerm@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Respiratory Sciences. Date: November 15–16, 2018. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ghenima Dirami, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD 20892, 240–498– 7546, diramig@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Animal/Biological and Related Resources. Date: November 15, 2018. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Baishali Maskeri, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2022, E:\FR\FM\23OCN1.SGM 23OCN1

Agencies

[Federal Register Volume 83, Number 205 (Tuesday, October 23, 2018)]
[Notices]
[Pages 53489-53490]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-23066]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Dr. Vince Contreras, 240-669-2823; 
[email protected]. Licensing information and copies of the U.S. 
patent application listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Fusion Glycoprotein Vaccine for Human Metapneumovirus

    Description of Technology: Human metapneumovirus (hMPV), a 
negative, single-stranded RNA virus, accounts for approximately 5-15% 
of infant respiratory tract infections and poses a severe risk of 
disease and hospitalization in both the elderly and the 
immunocompromised. Investigators at the Vaccine Research Center (VRC) 
of the National Institute of Allergy and Infectious Diseases (NIAID) 
have generated an hMPV fusion glycoprotein (``F protein'') stabilized 
in a prefusion conformation.
    Stabilizing this prefusion conformation of the F protein reveals an 
immunodominant site which makes it an ideal vaccine immunogen. The

[[Page 53490]]

prefusion stabilized F protein immunogen can be delivered as either an 
isolated homotrimer or trimers displayed on a nanoparticle. These 
immunogens elicit broad and potent hMPV-neutralizing antibodies.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:

 Vaccine for prevention of human metapneumovirus infection

    Competitive Advantages:

 No human metapneumovirus vaccine is currently available

    Development Stage:

 In vitro data available
 In vivo animal data available

    Inventors: Peter D. Kwong, (NIAID), Michael Gordon Joyce (NIAID), 
Peter L. Collins (NIAID), Ursula J. Buchholz (NIAID), Guillaume 
Stewart-Jones (NIAID), Baoshan Zhang (NIAID), Yongping Yang (NIAID), 
Davide Corti (Institute for Research in Biomedicine), Antonio 
Lanzavecchia (Institute for Research in Biomedicine).
    Intellectual Property: HHS Reference Number E-260-2014 includes 
U.S. Provisional Patent Application No. 62/096,744, filed December 24, 
2014; PCT Application No. PCT/IB2015/059991, filed December 24, 2015; 
U.S. Patent Application No 15/539,640 filed June 23, 2017; EPO Patent 
Application No. 15831073.0, filed 21 July 2017.
    Licensing Contact: Dr. Vince Contreras, 240-669-2823; 
[email protected].

    Dated: October 10, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-23066 Filed 10-22-18; 8:45 am]
 BILLING CODE 4140-01-P